Research Article

Autocrine Human Urotensin II Enhances Macrophage-Derived Foam Cell Formation in Transgenic Rabbits

Sihai Zhao,¹,² Yafeng Li,¹,² Shoucui Gao,¹ Xiaojing Wang,¹ Lijing Sun,¹ Daxing Cheng,¹ Liang Bai,¹ Hua Guan,¹ Rong Wang,¹ Jianglin Fan,³ and Enqi Liu¹,²

¹Labotatory for Lipid Metabolism and Atherosclerosis, Xi’an Jiaotong University Cardiovascular Research Center, Xi’an, Shaanxi 710061, China
²Laboratory Animal Center, Xi’an Jiaotong University School of Medicine, Xi’an, Shaanxi 710061, China
³Department of Molecular Pathology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi 409-3898, Japan

Correspondence should be addressed to Enqi Liu; liuenqi@mail.xjtu.edu.cn

Received 27 August 2015; Accepted 29 September 2015

Academic Editor: Ronald L. Klein

Copyright © 2015 Sihai Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Circulating urotensin II (UII) is involved in the development of atherosclerosis. However, the role of autocrine UII in the development of atherosclerosis remains unclear. Here, we tested the hypothesis that autocrine UII would promote atherosclerosis. Transgenic rabbits were created as a model to study macrophage-specific expressing human UII (hUII) and used to investigate the role of autocrine UII in the development of atherosclerosis. Transgenic rabbits and their nontransgenic littermates were fed a high cholesterol diet to induce atherosclerosis. Comparing the transgenic rabbits with their nontransgenic littermates, it was observed that hUII expression increased the macrophage-positive area in the atherosclerotic lesions by 45% and the positive area ratio by 56% in the transgenic rabbits. Autocrine hUII significantly decreased the smooth muscle cell-positive area ratio in transgenic rabbits (by 54%), without affecting the plasma levels of total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and glucose and adipose tissue contents. These results elucidated for the first time that autocrine UII plays an important role in the development of atherosclerosis by increasing the accumulation of macrophage-derived foam cell.

1. Introduction

Atherosclerotic cardiovascular diseases, including heart attack, stroke, and peripheral vascular insufficiency, continue to be the principal cause of death and disability in the world. Vasoactive peptides play an important role in the development of atherosclerosis [1]. Urotensin II (UII) is a vasoactive cyclic peptide composed of 11 amino acids, which was initially isolated from the neurosecretory system of goby fish [2, 3]. UII was expressed predominantly in the cardiovascular and central nervous systems as well as in endocrine tissue and, particularly, in human atherosclerotic lesions [4, 5]. Epidemiological, clinical, and experimental studies have shown that an increasing level of circulating UII is involved in the development of atherosclerosis [5–10]. Circulating UII increases plasma reactive oxygen species (ROS) and oxidized low-density lipoprotein (ox-LDL) and upregulates the expression of vascular cell adhesion protein-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), scavenger receptors (CD36 and scavenger receptor class A), and acyl-CoA, which are important molecules in the initiation and progression stages of atherosclerosis lesion formation [8–10]. Whether autocrine UII plays an important role in the development of atherosclerosis remains unclear. Macrophage-derived foam cells is one of the main cell components in atherosclerosis lesions and its differentiation, proliferation, and accumulation affect atherosclerosis plaque formation, progression, and destabilization [11]. We hypothesized that autocrine UII might promote atherosclerosis. In this study, we created transgenic rabbits to investigate the role of autocrine UII in the development of atherosclerosis by the macrophage-specific expression of human UII. Our results showed that macrophage-autocrine UII increased
the accumulation of macrophage-derived foam cells in arch atherosclerotic plaques.

2. Materials and Methods

2.1. Generation and Identification of Human UII Transgenic Rabbits. Japanese white rabbits were supplied by the Laboratory Animal Center of Xi’an Jiaotong University. The generation of the transgenic rabbits expressing human UII (hUII) was conducted in our laboratory by microinjection, as described in a previous study [12]. For the macrophage-specific expression of hUII, 648 bp cDNA of the (NM_021995) hUII gene was cloned into EcoRV and SacII sites 3' of the human scavenger receptor promoter and 5' of the human growth hormone splicing and polyadenylation sites, with 4 copies of the chicken β globin insulator, which could prevent the position effect of transgenes [13]. The resultant fragment (Figure 1(a)) was isolated by digestion with Sal I, injected into fertilized rabbit zygotes, and reimplanted into foster mothers. The transgenic founders were identified from blood DNA by the polymerase chain reaction (PCR) method (primers: forward 5'-TTTCATCTTATGCTCTGTCAC 3', reverse 5' CTGGCAGTATCTGTAGAAGGGA 3'). The transgenic rabbits that had incorporated the transgene into the germ line were bred with nontransgenic rabbits. The hUII transgenic rabbits and their nontransgenic littersmates were fed a high cholesterol diet and underwent atherosclerosis analysis. The animal experiments were approved by the Laboratory Animal Administration Committee of Xi’an Jiaotong University and performed according to the Guidelines for Animal Experimentation of Xi’an Jiaotong University and the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH, Publication Number 85–23, revised 2011).

2.2. Isolation and Analysis of RNA. Peritoneal macrophages were harvested from the peritoneal cavity 4 days after injection of 4% Fluid's thiglycolate medium. Alveolar macrophages were collected by subjecting the lungs to lavage with 100 mL of phosphate buffered saline (PBS, pH 7.4). Peritoneal and alveolar macrophages were confirmed based on the criteria of morphology and nonspecific esterase reactivity. The total RNA from various tissues and isolated peritoneal and alveolar macrophages was rapidly isolated using TRIZol reagent (Invitrogen, USA) and reverse-transcribed into cDNA using a reverse transcription kit (Takara, Japan). The expression of hUII in the macrophages, heart, lung, liver, spleen, kidney, and small intestine was evaluated using quantitative real-time PCR. The following sets of primers were used: forward 5'-TTTCATCTTATGCTCTGTCAC 3', reverse 5' ATGTTGGAATCTCTGCTTCCC3', 259 bp; rabbit GAPDH forward 5'-ATACAGGCCACCAGAGACG3', reverse 5' GTGAGTCTCCCCCCGTCGTC 3', 146 bp. The cycling conditions were 95°C for 30 s, followed by 40 cycles of 95°C for 30 s, and 55°C for 40 s.

2.3. Western Blot Analysis of hUII. To identify the hUII expression levels in transgenic rabbits, protein samples extracted from alveolar macrophages of the transgenic rabbits and their nontransgenic littermates were prepared, as described previously, and analyzed by electrophoresis on 10% SDS-polyacrylamide gels, followed by Western blotting and probing with a polyclonal antibody against hUII (Atlas Antibodies, Sweden) [10].

2.4. Induction of Atherosclerosis. The hUII transgenic rabbits (n = 5, male) and their nontransgenic littersmates (n = 5, male) were fed a high cholesterol diet (HCD, 0.3% cholesterol) for 16 weeks to induce atherosclerosis.

2.5. Measurement of Plasma Parameters. After overnight fasting, blood samples were collected via the auricular artery every two weeks. The blood samples were stored on ice and centrifuged (3000 rpm, 15 minutes, 4°C) to obtain the plasma. The plasma triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and glucose levels were measured using commercial assay kits (Biosino Biotechnology & Science Inc., Beijing, China).

2.6. Measurement of Blood Pressure. At the end of the experiment, rabbits were anesthetized with sodium pentobarbitone. The blood pressure was examined directly via a carotid artery catheter, with a pressure transducer and amplifier attached to a digital PowerLab data acquisition system (ML870 PowerLab, ADInstruments, Australia). The data were collected 10 minutes after the rabbits became calm and there were no blood pressure fluctuations. The blood pressure measurements were calculated using Chart 5 Pro v5.5 software (ADInstruments, Australia).

2.7. Analysis of Atherosclerosis Lesions. At the end of the experiment, the rabbits were sacrificed by an overdose of sodium pentobarbitone for the analysis of the atherosclerotic arterial lesions. The aortas were en face stained with Sudan IV (Yongsheng Chemical Co., China) for evaluation of the gross atherosclerotic lesions, as described previously [10, 14]. Briefly, the whole aortas were photographed using a digital camera and the sudanophilic area was measured using an image analysis system. For the microscopic quantification of the lesion area, each segment of the rabbit aortas was cut into cross sections (8 to 10 for the aortic arch and 20 for the thoracic aorta, as described previously) [14]. The sections were embedded in paraffin and stained with hematoxylin and eosin (H&E). For the microscopic evaluation of the cellular components in the lesions, serial paraffin sections of the thoracic aortas were immunohistochemically stained with antibodies (Abs) against macrophages (Mac) (RAMII, Dako, Carpinteria, CA, USA) and smooth muscle cells (SMCs) (α-actin, Thermo Fisher Scientific Pierce, Rockford, IL, USA). The sections for microscopic quantification were examined and photographed under a microscope equipped with a digital camera (Nikon, Tokyo, Japan) and measured with image analysis software (WinROOF Ver. 6.5, 130 Mitani Co. Ltd. Fukui, Japan).
2.8. Analysis of Adipose Tissue Contents and Organs. At the end of the experiment, the heart, liver, lung, kidney, and spleen were carefully removed, weighed, and fixed in 10% buffered formalin for subsequent histological examination. Adipose tissue from the subcutaneous (inguinal and interscapular adipose tissue) and visceral regions (the mesentery and retroperitoneal adipose tissue samples) were collected and weighed-wet [14]. The tissue samples were embedded in paraffin, and the sections (4 μm thick) were stained routinely by hematoxylin and eosin (H&E).

2.9. Statistical Analysis. The results were expressed as the means ± SEM. The statistical analysis was performed using Student’s t-test for the data with an equal F value or Welch’s t-test when the F value was not equal. A p value of less than 0.05 was considered statistically significant.

3. Results

3.1. Generation of Human UII Transgenic Rabbits. In this study, we successfully generated transgenic rabbit macrophage-specific expressing hUII. A total of 769 zygotes of rabbits were microinjected with fragmented hUII cDNA, and 40 pups were born. Two pups were found to be integrated with the transgene by PCR genotyping (Figure 1(b)). The hUII founder transgenic rabbits (designated L1D and L2C) were mated with wild type rabbits, and the germ line transmission was confirmed. The real-time PCR analysis showed that the hUII transgene in the transgenic rabbits was predominantly expressed in the isolated macrophages and less expressed in the aorta and macrophage-rich tissues (lung, spleen, and bone marrow tissues) (Figure 1(c)). The expression of hUII in the macrophages was confirmed as well by Western blot analysis (Figure 1(c)). The transgene did not affect the phenotype, breeding ability, and health of the rabbits. The transgenic rabbits and their nontransgenic littermates from the L1 line were used for this study.

3.2. Plasma Parameters. The plasma TC and TG levels were measured biweekly, and the LDL-C and HDL-C were measured every 4 weeks during the entire period of the experiment. As shown in Figure 2, the plasma levels of TC, TG, LDL-C, and HDL-C were not significantly different in the transgenic rabbits and their nontransgenic littermates at all the time points during the 16 weeks of HCD feeding. Additionally, the plasma glucose levels of the transgenic rabbits were similar to those of the nontransgenic rabbits (Figure 2).

3.3. Body Weight, Adipose Tissue Contents, Organs Weight, and Blood Pressure. As shown in Figure 3, the body weight and adipose tissue contents as well as the systolic and diastolic blood pressure were measured. There was no significant difference between the transgenic and the nontransgenic rabbits. The wet weights of the heart, liver, spleen, lung, and kidney were not significantly different (Figure 3).

3.4. Quantification of Atherosclerotic Lesions. The aortas of the rabbits were collected, and the lesions were characterized by the following: (1) Sudan IV staining of the positive area of the aortic arch and thoracic and abdominal aortas; (2) microscopic measurement of the intimal lesion size; and (3)
Figure 2: The TC, LDL-C, TG, HDL-C, and glucose plasma levels in the transgenic rabbits and their nontransgenic littermates. The data are expressed as the mean ± SEM, n = 5 for each group.
assessments of the lesional cellular components (macrophages and SMCs). The expression of the autocrine exogenous hUII did not significantly change the gross lesion area in the cholesterol fed rabbits (Figure 4(a)). The histological examinations revealed that the lesions of the rabbits consisted predominantly of fatty streaks (Figure 4(b)). The hUII expression in the transgenic rabbits did not significantly change the microscopic intimal lesions, compared with that in their nontransgenic littermates (Figures 4(c) and 4(d)). In the transgenic rabbits, compared to their nontransgenic littermates, the macrophage-positive area was increased by 45% and the positive-area ratio was significantly increased by 56% (Figure 4(e)). The autocrine hUII significantly decreased the SMC-positive area ratio in the transgenic rabbits by 54% (Figure 4(f)).

4. Discussion

As a vasoactive cyclic peptide, circulating UII is involved in the progression of atherosclerosis and identified to be a proatherogenic factor, based on the current information from several laboratories and our previous study [5–10]. The role of autocrine UII in the development of atherosclerosis remains unclear. In this study, we successfully created transgenic rabbits that expressed macrophage-specific hUII. This study found that macrophage- specific autocrine hUII enhances macrophage-derived foam cell formation in transgenic rabbits fed a high cholesterol diet and decreased the ratio of SMC-derived foam cells in atherosclerotic lesions. The effect of autocrine hUII in foam cell formation was independent of any change in the plasma TC, LDL-C, HDL-C, and TG levels. Autocrine hUII did not significantly affect the gross atherosclerotic lesions. Additionally, these data showed that autocrine hUII might increase susceptibility to the plaque rupture because the atherosclerotic lesions of the transgenic rabbits contained more macrophages than their nontransgenic littermates.

One of the important roles that circulating UII plays in the development of atherosclerosis is to promote macrophage-derived foam cell formation by regulation of
Figure 4: Representative aortic atherosclerosis lesions ((a), (b)) and their quantitative analysis ((c)–(f)). The data are expressed as the mean ± SEM. n = 5 for each group. Representative micrographs of the intimal lesions and the cellular components (a). The aortic sections were stained with H&E or immunohistochemically stained with Abs against macrophages or smooth muscle α-actin (b). The quantitative analysis of the aortic arch lesion area and the cellular composition of the macrophages and smooth muscle cells are shown at the bottom ((c)–(f)). n = 5 for each group. The data are expressed as the mean ± SEM. *P < 0.05 and **P < 0.01 versus the nontransgenic littermates. Mφ, macrophages; SMC, smooth muscle cell; Tg, transgenic.
the cholesterol metabolism and inflammation molecules [1, 10, 15]. Circulating UII was reported to suppress the ABCA1 expression via activation of the ERK/NF-κB pathway and to reduce the cholesterol efflux to promote macrophage-foam cell formation [15]. Circulating UII plays a novel role in the formation of macrophage-derived foam cells by upregulating the ACAT-1 expression via the UT receptor/G-protein/c-Src/PKC/MEK and ROCK pathways [16]. Circulating UII might increase the production of inflammatory cytokines via its receptors, such as VCAM-1, ICAM-1, endothelin-1, IL-6, and IL-1β [10, 16–19]. UII is secreted into the circulation from the heart and other tissues [5, 20]. The collected results suggest that one of the mechanisms of the contribution of circulating UII to the development of atherosclerosis was realized by promoting the formation of macrophage-derived foam cells. In this study, we first demonstrated that autocrine hUII enhanced macrophage-derived foam cell formation in transgenic rabbits.

The effect of autocrine hUII was shown more specifically in the promotion of the macrophage-derived foam cell formation than in the circulating UII, without any changes in the plasma lipid levels and blood pressure. The circulating UII was reported to have significant effects on the circulating plasma lipids, blood pressure, weight, visceral fat, proatherogenic cytokines, and glucose tolerance [21–26]. However, as a local peptide, the UII secreted by macrophages in atherosclerotic lesions predominantly affected the formation of a foam cell based on this study in transgenic rabbits. Enhancement of intimal macrophage accumulation caused by a high level of UII might increase the vulnerability of the plaques [11, 27, 28]. Matrix metalloproteinase 9, an important regulator of plaque stability, was increased by a high level of plasma UII [11]. Additionally, autocrine hUII might decrease plaque stability by enhancing macrophage-derived foam cell formation in transgenic rabbits fed a high cholesterol diet for an extended period of time. Another finding in this study was that autocrine hUII significantly decreased the SMC-derived foam cell stained positive area ratio in transgenic rabbits. The circulating UII was reported to promote vascular SMC proliferation through a store-operated calcium entry and epidermal growth factor receptor transactivation in rodent models [19, 29]. Our previous study found that increasing circulating UII by osmotic minipump infusion did not change the SMC-positive stained area in atherosclerotic lesions in rabbits [10]. These inconsistent findings might be because of the different characteristics of animal species. Local UII might promote the SMC phenotypic switching and some of them expressed the macrophage's markers [30]. In this study, the decrease of the SMC-positive stained area in the atherosclerotic lesions in transgenic rabbits might result from the increased proportion of macrophage-derived foam cells.

5. Conclusion

The results of this study showed that the autocrine hUII changes the cellular components in atherosclerotic lesions by enhancement of the macrophage-derived foam cell formation in transgenic rabbits. To the best of our knowledge, this study was the first to elucidate the role of autocrine UII in the development of atherosclerosis.

Conflict of Interests

The authors declare that they have no interests that may be perceived as posing a conflict of interests.

Authors’ Contribution

Sihai Zhao and Yafeng Li contributed equally to this work.

Acknowledgments

This work was supported in part by the National Natural Science Foundation of China (nos. 30900526 and 81370379), the Fundamental Research Fund for the Central Universities, and the Natural Science Foundation of Shaanxi Province (2012KJXX-07, 2014Q4137, and 2014FWPT07).

References

[1] T. Watanabe, K. Sato, F. Itoh et al., “Emerging roles for vasoactive peptides in diagnostic and therapeutic strategies against atherosclerotic cardiovascular diseases,” Current Protein and Peptide Science, vol. 14, no. 6, pp. 472–480, 2013.
[2] H. A. Bern and K. Lederis, “A reference preparation for the study of active substances in the caudal neurosecretory system of teleosts,” Journal of Endocrinology, vol. 45, no. 1, pp. 11–12, 1969.
[3] D. Pearson, J. E. Shively, B. R. Clark et al., “Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 8 I, pp. 5021–5024, 1980.
[4] R. S. Ames, H. M. Sarau, J. K. Chambers et al., “Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14,” Nature, vol. 401, no. 6750, pp. 282–286, 1999.
[5] J. J. Maguire, R. E. Kuc, K. E. Wiley, M. J. Kleinz, and A. P. Dav-enport, “Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries,” Peptides, vol. 25, no. 10, pp. 1767–1774, 2004.
[6] T. Suguro, T. Watanabe, Y. Ban et al., “Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension,” American Journal of Hypertension, vol. 20, no. 2, pp. 211–217, 2007.
[7] T. Suguro, T. Watanabe, S. Kodate et al., “Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes,” Clinical Science, vol. 115, no. 11, pp. 327–334, 2008.
[8] Y. Shiraishi, T. Watanabe, T. Suguro et al., “Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice,” Journal of Hypertension, vol. 26, no. 10, pp. 1955–1965, 2008.
[9] Z. You, J. Genest Jr., P. O. Barrette et al., “Genetic and pharmacological manipulation of urotensin II ameliorate the metabolic
and atherosclerosis sequelae in mice,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 32, no. 8, pp. 1809–1816, 2012.

[10] Y. Li, S. Zhao, Y. Wang et al., “Urotensin II promotes atherosclerosis in cholesterol-fed rabbits,” *PLoS ONE*, vol. 9, no. 4, Article ID e95089, 2014.

[11] K. J. Moore and I. Tabas, “Macrophages in the pathogenesis of atherosclerosis,” *Cell*, vol. 145, no. 3, pp. 341–355, 2011.

[12] J. Fan and T. Watanabe, “Transgenic rabbits as therapeutic protein bioreactors and human disease models,” *Pharmacology & Therapeutics*, vol. 99, no. 3, pp. 261–282, 2003.

[13] F. Recillas-Targa, M. J. Pikkaart, B. Burgess-Beusse et al., “Position-effect protection and enhancer blocking by the chicken $\beta$-globin insulator are separable activities,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 10, pp. 6883–6888, 2002.

[14] S. Zhao, C. Zhang, Y. Lin et al., “The effects of rosiglitazone on aortic atherosclerosis of cholesterol-fed rabbits,” *Thrombosis Research*, vol. 123, no. 2, pp. 281–287, 2008.

[15] Y. Wang, J.-F. Wu, Y.-Y. Tang et al., “Urotensin II increases foam cell formation by repressing ABCA1 expression through the ERK/NF-$\kappa$B pathway in THP-1 macrophages,” *Biochemical and Biophysical Research Communications*, vol. 452, no. 4, pp. 998–1003, 2014.

[16] T. Watanabe, T. Suguro, T. Kanome et al., “Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages,” *Hypertension*, vol. 46, no. 4, pp. 738–744, 2005.

[17] R. S. Kiss, Z. You, J. Genest Jr., D. J. Behm, and A. Giaid, “Urotensin II differentially regulates macrophage and hepatic cholesterol homeostasis,” *Peptides*, vol. 32, no. 5, pp. 956–963, 2011.

[18] D. G. Johns, Z. Ao, D. Naselsky et al., “Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators,” *Naunyn-Schmiedeberg's Archives of Pharmacology*, vol. 370, no. 4, pp. 238–250, 2004.

[19] C.-S. Tsai, S.-H. Loh, J.-C. Liu et al., “Urotensin II-induced endothelin-1 expression and cell proliferation via epidermal growth factor receptor transactivation in rat aortic smooth muscle cells,” *Atherosclerosis*, vol. 206, no. 1, pp. 86–94, 2009.

[20] Y.-H. Chen, T. G. Yandle, A. M. Richards, and S. C. Palmer, “Urotensin II immunoreactivity in the human circulation: evidence for widespread tissue release,” *Clinical Chemistry*, vol. 55, no. 11, pp. 2040–2048, 2009.

[21] L. Tran, A. R. Kompa, W. Kemp, A. Phrommintikul, B. H. Wang, and H. Krum, “Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats,” *The American Journal of Physiology—Heart and Circulatory Physiology*, vol. 298, no. 2, pp. H608–H613, 2010.

[22] J. Cheriyian, T. J. Burton, T. J. Bradley et al., “The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans,” *British Journal of Clinical Pharmacology*, vol. 68, no. 4, pp. 518–523, 2009.

[23] G. Gendron, F. Gobeil Jr., S. Bélangert, S. Gagnon, D. Regoli, and P. D’Orléans-Juste, “Urotensin II-induced hypotensive responses in Wistar-Kyoto (Wky) and spontaneously hypertensive (Shr) rats,” *Peptides*, vol. 26, no. 8, pp. 1468–1474, 2005.

[24] S. Matsusaka and I. Wakabayashi, “Enhancement of vascular smooth muscle cell migration by urotensin II,” *Naunyn-Schmiedeberg's Archives of Pharmacology*, vol. 373, no. 5, pp. 381–386, 2006.

[25] A. M. D. Watson, M. J. McKinley, and C. N. May, “Effect of central urotensin II on heart rate, blood pressure and brain Fos immunoreactivity in conscious rats,” *Neuroscience*, vol. 155, no. 1, pp. 241–249, 2008.

[26] T. Hirose, K. Takahashi, N. Mori et al., “Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: comparison with endothelin-1,” *Peptides*, vol. 30, no. 6, pp. 1124–1129, 2009.

[27] G. Chinetti-Gbaguidi, S. Colín, and B. Staels, “Macrophage subsets in atherosclerosis,” *Nature Reviews: Cardiology*, vol. 12, no. 1, pp. 10–17, 2015.

[28] V. M. Olkkonen, “Macrophage oxysterols and their binding proteins: roles in atherosclerosis,” *Current Opinion in Lipidology*, vol. 23, no. 5, pp. 462–470, 2012.

[29] M. Rodríguez-Moyano, I. Díaz, N. Dionisio et al., “Urotensin-II promotes vascular smooth muscle cell proliferation through store-operated calcium entry and EGFR transactivation,” *Cardiovascular Research*, vol. 100, no. 2, pp. 297–306, 2013.

[30] D. Gomez and G. K. Owens, “Smooth muscle cell phenotypic switching in atherosclerosis,” *Cardiovascular Research*, vol. 95, no. 2, pp. 156–164, 2012.